While there are a few common and well-known checkpoints for bladder cancer, there are also many more than PD-1, PD-L1 and CTLA-4.
When it comes to biomarkers used to determine treatment strategy in bladder cancer, there is more than PD-1, PD-L1 and CTLA-4, says Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Researchers have not yet examined or reached a full understanding of all the possible checkpoints, especially since the targets — like the immune response in general – are very dynamic and change over time.
FDA Approves 3 Treatments, Cancer Vaccine Shows Promise
December 20th 2023The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Listen